raloxifene
Preliminary studies of a new selective estrogen receptor modulator (SERM 2),       raloxifene, developed for the prevention of osteoporosis, have shown that the       breast cancer rate was reduced by more than 50% without any concomitant increase        in endometrial cancer.
Preliminary studies of a new  @OBJECT$  @PREDICAT$  @SUBJECT$ , developed for the prevention of osteoporosis, have shown that the       breast cancer rate was reduced by more than 50% without any concomitant increase        in endometrial cancer.